{"data":[{"accessionNo":"0001104659-26-115087","formType":"SCHEDULE 13D/A","amendmentNo":8,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-10-07","reportingPerson":"Harwin Peter Evan","reportingCik":"0001663607","personType":"IN","sharesOwned":10185961,"percentOfClass":9.99,"filedAt":"2026-10-09","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001104659-26-115087","formType":"SCHEDULE 13D/A","amendmentNo":8,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-10-07","reportingPerson":"Kiselak Tomas","reportingCik":"0001830177","personType":"IN","sharesOwned":10185961,"percentOfClass":9.99,"filedAt":"2026-10-09","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001104659-26-115087","formType":"SCHEDULE 13D/A","amendmentNo":8,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-10-07","reportingPerson":"Fairmount Funds Management LLC","reportingCik":"0001802528","personType":"IA","sharesOwned":9354200,"percentOfClass":9.19,"filedAt":"2026-10-09","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001104659-26-115087","formType":"SCHEDULE 13D/A","amendmentNo":8,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-10-07","reportingPerson":"Fairmount Healthcare Fund II L.P.","reportingCik":"0001769651","personType":"PN","sharesOwned":9354200,"percentOfClass":9.19,"filedAt":"2026-10-09","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001104659-26-112828","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636282","issuerName":"Spyre Therapeutics, Inc.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-09-24","reportingPerson":"Paradigm BioCapital Advisors LP","reportingCik":null,"personType":"PN","sharesOwned":4457450,"percentOfClass":5.1,"filedAt":"2026-10-01","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001104659-26-112828","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636282","issuerName":"Spyre Therapeutics, Inc.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-09-24","reportingPerson":"Paradigm BioCapital Advisors GP LLC","reportingCik":null,"personType":"OO","sharesOwned":4457450,"percentOfClass":5.1,"filedAt":"2026-10-01","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001104659-26-112828","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636282","issuerName":"Spyre Therapeutics, Inc.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-09-24","reportingPerson":"Senai Asefaw, M.D.","reportingCik":null,"personType":"IN","sharesOwned":4457450,"percentOfClass":5.1,"filedAt":"2026-10-01","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001104659-26-112828","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636282","issuerName":"Spyre Therapeutics, Inc.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-09-24","reportingPerson":"Paradigm BioCapital International Fund Ltd.","reportingCik":null,"personType":"CO","sharesOwned":3928646,"percentOfClass":4.5,"filedAt":"2026-10-01","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001193125-26-352655","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 Par Value Per Share","eventDate":"2026-06-30","reportingPerson":"Perceptive Advisors LLC","reportingCik":null,"personType":"IA","sharesOwned":4319496,"percentOfClass":4.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001193125-26-352655","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 Par Value Per Share","eventDate":"2026-06-30","reportingPerson":"Joseph Edelman","reportingCik":null,"personType":"IN","sharesOwned":4319496,"percentOfClass":4.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001193125-26-352655","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 Par Value Per Share","eventDate":"2026-06-30","reportingPerson":"Perceptive Life Sciences Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":4319496,"percentOfClass":4.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001493215-26-000157","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001636282","issuerName":"Spyre Therapeutics, Inc.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-06-30","reportingPerson":"RTW Investments, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":4251996,"percentOfClass":4.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001493215-26-000157","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001636282","issuerName":"Spyre Therapeutics, Inc.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-06-30","reportingPerson":"Roderick Wong","reportingCik":null,"personType":"HC,IN","sharesOwned":4251996,"percentOfClass":4.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001104659-26-076961","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-06-23","reportingPerson":"Peter Evan Harwin","reportingCik":"0001663607","personType":"IN","sharesOwned":9667201,"percentOfClass":9.99,"filedAt":"2026-06-23","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001104659-26-076961","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-06-23","reportingPerson":"Tomas Kiselak","reportingCik":"0001830177","personType":"IN","sharesOwned":9667201,"percentOfClass":9.99,"filedAt":"2026-06-23","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001104659-26-076961","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-06-23","reportingPerson":"Fairmount Funds Management LLC","reportingCik":"0001802528","personType":"IA","sharesOwned":8835440,"percentOfClass":9.15,"filedAt":"2026-06-23","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001104659-26-076961","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-06-23","reportingPerson":"Fairmount Healthcare Fund II L.P.","reportingCik":"0001769651","personType":"PN","sharesOwned":8835440,"percentOfClass":9.15,"filedAt":"2026-06-23","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001193125-26-170304","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 Par Value Per Share","eventDate":"2026-04-15","reportingPerson":"Perceptive Advisors LLC","reportingCik":null,"personType":"IA","sharesOwned":4319496,"percentOfClass":5,"filedAt":"2026-04-22","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001193125-26-170304","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 Par Value Per Share","eventDate":"2026-04-15","reportingPerson":"Joseph Edelman","reportingCik":null,"personType":"IN","sharesOwned":4319496,"percentOfClass":5,"filedAt":"2026-04-22","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001193125-26-170304","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 Par Value Per Share","eventDate":"2026-04-15","reportingPerson":"Perceptive Life Sciences Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":4319496,"percentOfClass":5,"filedAt":"2026-04-22","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001104659-26-045578","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-04-16","reportingPerson":"Tomas Kiselak","reportingCik":"0001830177","personType":"IN","sharesOwned":9016702,"percentOfClass":9.99,"filedAt":"2026-04-20","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001104659-26-045578","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-04-16","reportingPerson":"Peter Harwin","reportingCik":"0001663607","personType":"IN","sharesOwned":9016702,"percentOfClass":9.99,"filedAt":"2026-04-20","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001104659-26-045578","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-04-16","reportingPerson":"Fairmount Funds Management LLC","reportingCik":"0001802528","personType":"IA","sharesOwned":8184941,"percentOfClass":9.09,"filedAt":"2026-04-20","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001104659-26-045578","formType":"SCHEDULE 13D/A","amendmentNo":6,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-04-16","reportingPerson":"Fairmount Healthcare Fund II L.P.","reportingCik":"0001769651","personType":"PN","sharesOwned":8184941,"percentOfClass":9.09,"filedAt":"2026-04-20","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0000102909-26-002337","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636282","issuerName":"Spyre Therapeutics Inc","ticker":"SYRE","cusip":"00773J202","securityClass":"Common Stock","eventDate":"2026-03-13","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-03-27","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001214659-26-002024","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636282","issuerName":"Spyre Therapeutics, Inc.","ticker":"SYRE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"KEVIN TANG","reportingCik":null,"personType":"IN","sharesOwned":1892200,"percentOfClass":2.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001214659-26-002024","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636282","issuerName":"Spyre Therapeutics, Inc.","ticker":"SYRE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"TANG CAPITAL MANAGEMENT, LLC","reportingCik":null,"personType":"OO","sharesOwned":1892200,"percentOfClass":2.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001214659-26-002024","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636282","issuerName":"Spyre Therapeutics, Inc.","ticker":"SYRE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"TANG CAPITAL PARTNERS, LP","reportingCik":null,"personType":"PN","sharesOwned":1012338,"percentOfClass":1.3,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001214659-26-002024","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636282","issuerName":"Spyre Therapeutics, Inc.","ticker":"SYRE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"TANG CAPITAL PARTNERS INTERNATIONAL, LP","reportingCik":null,"personType":"PN","sharesOwned":879862,"percentOfClass":1.1,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001214659-26-002024","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636282","issuerName":"Spyre Therapeutics, Inc.","ticker":"SYRE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"TANG CAPITAL PARTNERS IV, INC","reportingCik":null,"personType":"CO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001214659-26-002024","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001636282","issuerName":"Spyre Therapeutics, Inc.","ticker":"SYRE","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"TANG CAPITAL PARTNERS III, INC","reportingCik":null,"personType":"CO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001104659-25-100449","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-15","reportingPerson":"Peter Evan Harwin","reportingCik":"0001663607","personType":"IN","sharesOwned":8106882,"percentOfClass":9.99,"filedAt":"2025-10-17","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001104659-25-100449","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-15","reportingPerson":"Tomas Kiselak","reportingCik":"0001830177","personType":"IN","sharesOwned":8106882,"percentOfClass":9.99,"filedAt":"2025-10-17","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001104659-25-100449","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-15","reportingPerson":"Fairmount Funds Management LLC","reportingCik":"0001802528","personType":"IA","sharesOwned":7272341,"percentOfClass":8.99,"filedAt":"2025-10-17","canonicalUrl":"https://xoomar.com/markets/stocks/syre"},{"accessionNo":"0001104659-25-100449","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001636282","issuerName":"SPYRE THERAPEUTICS, INC.","ticker":"SYRE","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-10-15","reportingPerson":"Fairmount Healthcare Fund II L.P.","reportingCik":"0001769651","personType":"PN","sharesOwned":7272341,"percentOfClass":8.99,"filedAt":"2025-10-17","canonicalUrl":"https://xoomar.com/markets/stocks/syre"}],"updatedAt":"2026-10-29T05:52:31.008Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/syre","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}